Filing Flows › Companies › Bausch Health Companies › Timeline
Bausch Health Companies stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+22.3% to $8.18
Bausch Health Companies (BHC) stock rose 22% over the last 252 sessions, to $8.18. On the way it reported 4 quarters, its insiders filed 1 open-market trade and 1 Form 144 notice of planned sales, and the company filed 4 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Oct 28, 2026 | Earnings | Earnings: beat the EPS estimate by 42.5% | +9.2% (+8.9% vs SPY) | +25.5% (+27.5% vs SPY) | — |
| Aug 19, 2026 | Form 144 | Form 144: Aimee J. Lenar plans to sell $259K | −0.6% (−0.8% vs SPY) | −2.9% (−2.7% vs SPY) | −20.4% (−19.8% vs SPY) |
| Jul 29, 2026 | Earnings | Earnings: beat the EPS estimate by 25.1% | +3.5% (+5.0% vs SPY) | +35.4% (+31.4% vs SPY) | +36.5% (+33.1% vs SPY) |
| Jul 1, 2026 | 8-K | Directors and officers: departures, appointments, pay | +2.7% (+2.8% vs SPY) | +1.9% (+1.1% vs SPY) | +36.8% (+36.6% vs SPY) |
| Apr 29, 2026 | Earnings | Earnings: beat the EPS estimate by 12.8% | −1.4% (−1.4% vs SPY) | −0.5% (−2.2% vs SPY) | −4.7% (−10.5% vs SPY) |
| Mar 2, 2026 | 8-K | Directors and officers: departures, appointments, pay | −3.8% (−2.9% vs SPY) | −10.6% (−9.4% vs SPY) | −9.7% (−4.6% vs SPY) |
| Feb 18, 2026 | Earnings | Earnings: missed the EPS estimate by -12.8% | +3.3% (+2.8% vs SPY) | +0.5% (−0.2% vs SPY) | −16.3% (−13.1% vs SPY) |
| Jan 2, 2026 | 8-K | Material definitive agreement | +2.6% (+1.9% vs SPY) | +2.7% (+1.2% vs SPY) | −23.5% (−24.4% vs SPY) |
| Dec 29, 2025 | 8-K | Material definitive agreement | −1.0% (−0.6% vs SPY) | +2.7% (+3.1% vs SPY) | −24.1% (−24.8% vs SPY) |
| Nov 25, 2025 | Insider buy | Paulson & Co. Inc. bought $15.6M | +3.4% (+2.4% vs SPY) | +12.2% (+10.3% vs SPY) | +16.2% (+12.7% vs SPY) |
Insiders’ record here
In the year on the chart, Bausch Health Companies' insiders reported 1 open-market buy ($15.6M) and 0 sales ($0). Of the 1 old enough to score, 0 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was −7.8% and after a sale —.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Bausch Health Companies: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.